FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

AbstractThe mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression. Preclinical evidence suggests that baseline elevated tumor glucose metabolism as quantified by FDG-PET ([18F] fluorodeoxy-glucose positron emission tomography) may predict antitumor activity. Metastatic RCC (mRCC) patients refractory to vascular endothelial growth factor (VEGF) pathway inhibition were treated with standard dose everolimus. FDG-PET scans were obtained at baseline and 2weeks; serial computed tomography (CT) scans were obtained at baseline and every 8weeks. Maximum standardized uptake value (SUVmax) of the most FDG avid lesion, average SUVmax of all measured lesions and their corresponding 2-week relative changes were examined for association with 8-week change in tumor size. A total of 63 patients were enrolled; 50 were evaluable for the primary endpoint of which 48 had both PET scans. Patient characteristics included the following: 36 (72%) clear cell histology and median age 59 (range: 37–80). Median pre- and 2-week treatment average SUVmax were 6.6 (1–17.9) and 4.2 (1–13.9), respectively. Response evaluation criteria in solid tumors (RECIST)-based measurements demonstrated an average change in tumor burden of 0.2% (−32.7% to 35.9%) at 8weeks. Relative change in average SUVmax was the best predictor of change in tumor burden (all evaluable P=0.01; clear cell subtype P=0.02), with modest correlation. Baseline average SUVmax was correlated with overall survival and progression-free survival (PFS) (P=0.023; 0.020), but not with change in tumor burden. Everolimus therapy decreased SUVs on follow-up PET scans in mRCC patients, but changes were only modestly correlated with changes in tumor size. Thus, clinical use of FDG-PET-based biomarkers is challenged by high variability.In this phase II trial, FDG-PET was explored as a predictive biomarker for response to everolimus (mTOR inhibition) in metastatic renal cell carcinoma. Everolimus therapy decreased SUVs on follow-up FDG-PET scans in these patients. SUV changes were modestly correlated with changes in tumor size and baseline average SUVmax values were correlated with overall survival

Audiovisual crossmodal correspondences and sound symbolism: a study using the implicit association test

Parise C, Spence C. Audiovisual crossmodal correspondences and sound symbolism: a study using the implicit association test. Experimental Brain Research. 2012;220(3-4):319-333.A growing body of empirical research on the topic of multisensory perception now shows that even non-synaesthetic individuals experience crossmodal correspondences, that is, apparently arbitrary compatibility effects between stimuli in different sensory modalities. In the present study, we replicated a number of classic results from the literature on crossmodal correspondences and highlight the existence of two new crossmodal correspondences using a modified version of the implicit association test (IAT). Given that only a single stimulus was presented on each trial, these results rule out selective attention and multisensory integration as possible mechanisms underlying the reported compatibility effects on speeded performance. The crossmodal correspondences examined in the present study all gave rise to very similar effect sizes, and the compatibility effect had a very rapid onset, thus speaking to the automatic detection of crossmodal correspondences. These results are further discussed in terms of the advantages of the IAT over traditional techniques for assessing the strength and symmetry of various crossmodal correspondences